CATALYST PHARMACEUTICALS, INC.: 10-K filed 2017-03-15

Name: CATALYST PHARMACEUTICALS, INC.: 10-K filed 2017-03-15
Creator: CATALYST PHARMACEUTICALS, INC.

What CATALYST PHARMACEUTICALS, INC. reported in its annual report filed 2017-03-15 (fiscal FY 2016): 29 published measures, 99 facts as tagged in accession 0001193125-17-083667.

This filing

Form: 10-K (annual report)
Filed: 2017-03-15
Fiscal period: fiscal FY 2016
Accession: 0001193125-17-083667 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CATALYST PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2016-12-31	41,706,853	USD
At 2015-12-31	60,101,570	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2016-12-31	2,397,923	USD
At 2015-12-31	4,625,259	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2016-12-31	39,308,930	USD
At 2015-12-31	55,476,311	USD
At 2014-12-31	35,242,330	USD
At 2013-12-31	21,391,252	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2016-12-31	13,893,064	USD
At 2015-12-31	28,235,016	USD
At 2014-12-31	9,096,778	USD
At 2013-12-31	2,215,958	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2016-10-01 to 2016-12-31	-4,163,320	USD	92
2016-01-01 to 2016-12-31	-18,072,452	USD	366
2016-07-01 to 2016-09-30	-3,953,981	USD	92
2016-04-01 to 2016-06-30	-4,568,914	USD	91
2016-01-01 to 2016-03-31	-5,386,237	USD	91
2015-10-01 to 2015-12-31	-5,815,158	USD	92
2015-01-01 to 2015-12-31	-20,232,958	USD	365
2015-07-01 to 2015-09-30	-4,449,038	USD	92
2015-04-01 to 2015-06-30	-4,558,503	USD	91
2015-01-01 to 2015-03-31	-5,410,259	USD	90
2014-01-01 to 2014-12-31	-15,509,061	USD	365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2016-01-01 to 2016-12-31	96,061	USD	366
2015-01-01 to 2015-12-31	23,465	USD	365
2014-01-01 to 2014-12-31	57,323	USD	365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Unit	Days
2016-10-01 to 2016-12-31	USD	92
2016-01-01 to 2016-12-31	USD	366
2016-07-01 to 2016-09-30	USD	92
2016-04-01 to 2016-06-30	USD	91
2016-01-01 to 2016-03-31	USD	91
2015-10-01 to 2015-12-31	USD	92
2015-01-01 to 2015-12-31	USD	365
2015-07-01 to 2015-09-30	USD	92
2015-04-01 to 2015-06-30	USD	91
2015-01-01 to 2015-03-31	USD	90
2014-01-01 to 2014-12-31	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2016-12-31	-108,148,070	USD
At 2015-12-31	-90,075,618	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Unit	Days
2016-01-01 to 2016-12-31	USD	366
2015-01-01 to 2015-12-31	USD	365
2014-01-01 to 2014-12-31	USD	365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2016-12-31	244,204	USD
At 2015-12-31	191,549	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2016-01-01 to 2016-12-31	1,836,085	USD	366
2015-01-01 to 2015-12-31	1,585,458	USD	365
2014-01-01 to 2014-12-31	777,969	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2016-10-01 to 2016-12-31	-4,314,199	USD	92
2016-01-01 to 2016-12-31	-19,280,201	USD	366
2016-07-01 to 2016-09-30	-3,914,014	USD	92
2016-04-01 to 2016-06-30	-4,814,452	USD	91
2016-01-01 to 2016-03-31	-6,237,536	USD	91
2015-10-01 to 2015-12-31	-6,191,679	USD	92
2015-01-01 to 2015-12-31	-20,398,352	USD	365
2015-07-01 to 2015-09-30	-5,017,428	USD	92
2015-04-01 to 2015-06-30	-4,897,330	USD	91
2015-01-01 to 2015-03-31	-4,291,915	USD	90
2014-01-01 to 2014-12-31	-14,591,428	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2016-12-31	41,453,761	USD
At 2015-12-31	59,901,133	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2016-12-31	2,094,535	USD
At 2015-12-31	3,440,603	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2016-12-31	933,176	USD
At 2015-12-31	1,794,127	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2016-01-01 to 2016-12-31	19,280,201	USD	366
2015-01-01 to 2015-12-31	20,398,352	USD	365
2014-01-01 to 2014-12-31	14,591,428	USD	365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2016-01-01 to 2016-12-31	11,369,941	USD	366
2015-01-01 to 2015-12-31	11,801,342	USD	365
2014-01-01 to 2014-12-31	10,117,774	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2016-12-31	82,972,316	shares
At 2015-12-31	82,850,619	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2016-12-31	147,374,028	USD
At 2015-12-31	145,469,078	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2016-12-31	357,684	USD
At 2015-12-31	261,623	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2016-12-31	113,480	USD
At 2015-12-31	70,074	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2016-12-31	1,161,359	USD
At 2015-12-31	1,646,476	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2016-12-31	1,047,944	USD
At 2015-12-31	1,504,738	USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

Period	Value	Unit	Days
At 2016-12-31	0	USD
At 2015-12-31	0	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2016-01-01 to 2016-12-31	-18,072,452	USD	366
2015-01-01 to 2015-12-31	-20,232,958	USD	365
2014-01-01 to 2014-12-31	-15,509,061	USD	365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2016-01-01 to 2016-12-31	7,910,260	USD	366
2015-01-01 to 2015-12-31	8,597,010	USD	365
2014-01-01 to 2014-12-31	4,473,654	USD	365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2016-01-01 to 2016-12-31	43,406	USD	366
2015-01-01 to 2015-12-31	34,468	USD	365
2014-01-01 to 2014-12-31	26,574	USD	365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2016-01-01 to 2016-12-31	321,612	USD	366
2015-01-01 to 2015-12-31	100,389	USD	365
2014-01-01 to 2014-12-31	76,233	USD	365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2016-01-01 to 2016-12-31	-860,951	USD	366
2015-01-01 to 2015-12-31	-20,083	USD	365
2014-01-01 to 2014-12-31	963,421	USD	365

Inspect the source

Entity: CATALYST PHARMACEUTICALS, INC. / CIK 0001369568
Captured: 2026-09-21T17:19:25.463Z
SEC response SHA-256: 7cf76a511a9127dd31ed7d53955bbe348f790d8d7fd354d359e6674e7b2af9c9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001369568.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))